Alnylam Pharmaceuticals | ALNY - Ebit


Alnylam Pharmaceuticals reported $179.66M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Arrowhead Research USD -154.34M 13.08M Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Moderna USD 130M 945M Sep/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 1.78B 2.4B Sep/2026
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sanofi EUR 1.12B 1.06B Jun/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Takeda JPY 205.32B 3.9B Sep/2026
Tectonic Therapeutic USD -24.22M 3.08M Jun/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026
Xencor USD -36.6M 41.26M Jun/2026